Congenital generalised lipodystrophy – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Sun, 31 May 2026 04:01:47 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Congenital generalised lipodystrophy – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Metreleptin for Children Under 6 with Generalized Lipodystrophy and Related Diabetes or High Triglycerides https://clinicaltrials.eu/trial/study-on-metreleptin-for-children-under-6-with-generalized-lipodystrophy-and-related-diabetes-or-high-triglycerides/ Wed, 29 Apr 2026 14:24:25 +0000 https://clinicaltrials.eu/trial/study-on-metreleptin-for-children-under-6-with-generalized-lipodystrophy-and-related-diabetes-or-high-triglycerides/ This clinical trial is focused on studying a rare condition called generalized lipodystrophy, which affects the body’s ability to store fat properly. This can lead to other health issues like diabetes mellitus and high levels of fats in the blood, known as hypertriglyceridemia. The study will use a treatment called metreleptin, which is a protein-based medication. Metreleptin is given as an injection under the skin and is being tested to see how effective and safe it is for children under 6 years old who have generalized lipodystrophy.

The purpose of the study is to evaluate how well metreleptin works in managing the symptoms of generalized lipodystrophy and its associated conditions. Participants in the study will receive metreleptin injections over a period of 12 months. Throughout the study, researchers will monitor changes in the participants’ health, including their blood sugar levels and fat levels in the blood. The study aims to understand how metreleptin affects these health markers and whether it can help improve the quality of life for young children with this condition.

Participants will be closely observed by healthcare professionals to ensure their safety and to gather important information about how metreleptin works in their bodies. The study is open-label, meaning that both the participants and the researchers know that metreleptin is being administered. This trial is an important step in finding better treatments for children with generalized lipodystrophy and related health issues.

]]>